This DFS rate was significantly higher than the 80.4% rate for the 288 participants who instead received three cycles of docetaxel followed by three cycles of fluorouracil 500 mg/m 2 given on day 1 alongside the same doses of epirubicin and cyclophosphamide, and equated to a hazard ratio (HR) for a disease event or death of 0.66 in favor of the capecitabine combination.

Additionally, the investigators found that among the 288 patients who died, those who started taking an ICI in the preceding 30 days were significantly more likely to die in a hospital versus elsewhere, but this was not the case if they initiated ICI treatment in the final 90 days of their life.

They looked at the association between HIV status and mortality adjusting for patient age, sex, race/ethnicity, year of cancer diagnosis, median income, and treatment specifics among 288 HIV-infected and 307,980 HIV-uninfected patients.

The CheckMate 568 trial included 288 patients with treatment-naïve, recurrent stage IIIB or stage IV NSCLC.

The primary endpoint occurred in 4.2% of the 288 apixaban-treated patients and 10.2% of the 275 given placebo, and equated to a significant 59% reduction in the risk for major VTE with the DOAC.

The corresponding values for the 34 participants who additionally received LHRH therapy were 90% and 288 days.

They report in The New England Journal of Medicine that median OS was 9.1 months among the 288 patients with glioblastoma progression after chemoradiation who were randomly assigned to receive lomustine 90 mg/m 2 (maximum 160 mg) every 6 weeks plus bevacizumab 10 mg/kg every 2 weeks.